Literature DB >> 27239040

PIAS1 Promotes Lymphomagenesis through MYC Upregulation.

Andrea Rabellino1, Margherita Melegari2, Van S Tompkins3, Weina Chen4, Brian G Van Ness5, Julie Teruya-Feldstein6, Maralice Conacci-Sorrell7, Siegfried Janz3, Pier Paolo Scaglioni8.   

Abstract

The MYC proto-oncogene is a transcription factor implicated in a broad range of cancers. MYC is regulated by several post-translational modifications including SUMOylation, but the functional impact of this post-translational modification is still unclear. Here, we report that the SUMO E3 ligase PIAS1 SUMOylates MYC. We demonstrate that PIAS1 promotes, in a SUMOylation-dependent manner, MYC phosphorylation at serine 62 and dephosphorylation at threonine 58. These events reduce the MYC turnover, leading to increased transcriptional activity. Furthermore, we find that MYC is SUMOylated in primary B cell lymphomas and that PIAS1 is required for the viability of MYC-dependent B cell lymphoma cells as well as several cancer cell lines of epithelial origin. Finally, Pias1-null mice display endothelial defects reminiscent of Myc-null mice. Taken together, these results indicate that PIAS1 is a positive regulator of MYC.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27239040      PMCID: PMC4899214          DOI: 10.1016/j.celrep.2016.05.015

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  52 in total

1.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

Authors:  R Sears; F Nuckolls; E Haura; Y Taya; K Tamai; J R Nevins
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

2.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

Review 3.  PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription.

Authors:  J J Palvimo
Journal:  Biochem Soc Trans       Date:  2007-12       Impact factor: 5.407

4.  Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein.

Authors:  Joost Schimmel; Karolin Eifler; Jón Otti Sigurðsson; Sabine A G Cuijpers; Ivo A Hendriks; Matty Verlaan-de Vries; Christian D Kelstrup; Chiara Francavilla; René H Medema; Jesper V Olsen; Alfred C O Vertegaal
Journal:  Mol Cell       Date:  2014-02-27       Impact factor: 17.970

5.  A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.

Authors:  Jessica D Kessler; Kristopher T Kahle; Tingting Sun; Kristen L Meerbrey; Michael R Schlabach; Earlene M Schmitt; Samuel O Skinner; Qikai Xu; Mamie Z Li; Zachary C Hartman; Mitchell Rao; Peng Yu; Rocio Dominguez-Vidana; Anthony C Liang; Nicole L Solimini; Ronald J Bernardi; Bing Yu; Tiffany Hsu; Ido Golding; Ji Luo; C Kent Osborne; Chad J Creighton; Susan G Hilsenbeck; Rachel Schiff; Chad A Shaw; Stephen J Elledge; Thomas F Westbrook
Journal:  Science       Date:  2011-12-08       Impact factor: 47.728

6.  PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity.

Authors:  Bin Liu; Sheldon Mink; Kelly A Wong; Natalie Stein; Crescent Getman; Paul W Dempsey; Hong Wu; Ke Shuai
Journal:  Nat Immunol       Date:  2004-08-15       Impact factor: 25.606

7.  RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

Authors:  Georgia Konstantinidou; Giorgio Ramadori; Francesca Torti; Kim Kangasniemi; Rachel E Ramirez; Yiran Cai; Carmen Behrens; Michael T Dellinger; Rolf A Brekken; Ignacio I Wistuba; Adriana Heguy; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Discov       Date:  2013-01-28       Impact factor: 39.397

8.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.

Authors:  Asa Karlsson; Sylvie Giuriato; Flora Tang; Jingly Fung-Weier; Göran Levan; Dean W Felsher
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

9.  SUMOylation of Myc-family proteins.

Authors:  Arianna Sabò; Mirko Doni; Bruno Amati
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

10.  Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks.

Authors:  Yaron Galanty; Rimma Belotserkovskaya; Julia Coates; Sophie Polo; Kyle M Miller; Stephen P Jackson
Journal:  Nature       Date:  2009-12-17       Impact factor: 49.962

View more
  15 in total

1.  SUMO protease SENP1 deSUMOylates and stabilizes c-Myc.

Authors:  Xiao-Xin Sun; Yingxiao Chen; Yulong Su; Xiaoyan Wang; Krishna Mohan Chauhan; Juan Liang; Colin J Daniel; Rosalie C Sears; Mu-Shui Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-10       Impact factor: 11.205

Review 2.  The Role of PIAS SUMO E3-Ligases in Cancer.

Authors:  Andrea Rabellino; Cristina Andreani; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2017-03-22       Impact factor: 12.701

Review 3.  Sumoylation in Physiology, Pathology and Therapy.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Cells       Date:  2022-02-26       Impact factor: 6.600

4.  An in vitro Förster resonance energy transfer-based high-throughput screening assay identifies inhibitors of SUMOylation E2 Ubc9.

Authors:  Yu-Zhe Wang; Xiao Liu; George Way; Vipul Madarha; Qing-Tong Zhou; De-Hua Yang; Jia-Yu Liao; Ming-Wei Wang
Journal:  Acta Pharmacol Sin       Date:  2020-04-27       Impact factor: 7.169

Review 5.  The SUMO Pathway in Hematomalignancies and Their Response to Therapies.

Authors:  Mathias Boulanger; Rosa Paolillo; Marc Piechaczyk; Guillaume Bossis
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

Review 6.  SUMO and Transcriptional Regulation: The Lessons of Large-Scale Proteomic, Modifomic and Genomic Studies.

Authors:  Mathias Boulanger; Mehuli Chakraborty; Denis Tempé; Marc Piechaczyk; Guillaume Bossis
Journal:  Molecules       Date:  2021-02-05       Impact factor: 4.411

Review 7.  Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy.

Authors:  Xiao-Xin Sun; Yanping Li; Rosalie C Sears; Mu-Shui Dai
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

8.  Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility.

Authors:  Chongyang Li; Francis P McManus; Cédric Plutoni; Cristina Mirela Pascariu; Trent Nelson; Lara Elis Alberici Delsin; Gregory Emery; Pierre Thibault
Journal:  Nat Commun       Date:  2020-02-11       Impact factor: 14.919

Review 9.  Writing and erasing MYC ubiquitination and SUMOylation.

Authors:  Yingxiao Chen; Xiao-Xin Sun; Rosalie C Sears; Mu-Shui Dai
Journal:  Genes Dis       Date:  2019-07-24

10.  Cross-talk between Myc and p53 in B-cell lymphomas.

Authors:  Li Yu; Tian-Tian Yu; Ken H Young
Journal:  Chronic Dis Transl Med       Date:  2019-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.